Navigation Links
Arpida Announces Full Year 2007 Financial Results
Date:3/13/2008

REINACH, Switzerland, March 13 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) announced today its financial results for the year ending 31 December 2007.

2007 highlights

Major pipeline progress:

- Second pivotal Phase III trial with intravenous iclaprim in cSSSI achieves its pre-specified primary endpoint, as did the first

- Submission of New Drug Application (NDA) for intravenous iclaprim in cSSSI initiated

- First patients enrolled in a Phase II trial with intravenous iclaprim in HAP/VAP/HCAP, an important potential second indication
- Progress of Phase I programme with oral iclaprim

- Promising results of 'first-in-man' studies with AR-709

- Novel antibiotic AR-2474 achieves preclinical proof of concept

- Raised CHF 51.9 million in a secondary offering in March 2007 - Late-stage antifungal therapy added to pipeline via acquisition of TLT Medical Ltd.
- Extensive presence at scientific conferences

- Cash and financial investments of CHF 68.1 million at 31 December 2007

Post-Year-End Events

- Oral iclaprim moves into Phase II efficacy trial in cSSSI

2008 Outlook - Completion of patient enrolment in Phase II trial with oral iclaprim in cSSSI

- Completion of patient enrolment in Phase II trial with intravenous iclaprim in

HAP/VAP/HCAP

- Completion of patient enrolment in Phase III trial with TLT in onychomycosis

- Regulatory review of NDA for intravenous iclaprim in cSSSI in USA

- Submission of application for marketing authorisation in EU

Dr Khalid Islam, President and CEO, commented: "We're tremendously proud of the progress we've achieved in the year under review. By early 2008, we have one product candidate in an NDA filing process, one product in a Phase III, and two additional Phase II development programs. We are expecting the filing of the NDA for intravenous iclaprim in cSSSI to be completed shortly. Mark
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
2. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
3. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
4. Arpida-Supported CME Symposium Available Online
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
8. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
9. Arpida Interim Results for six Months to 30 June 2007
10. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
11. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4Reportlinker Adds Biotechnology Instrumentation - International Market Trends 2Reportlinker Adds Biotechnology Instrumentation - International Market Trends 3Reportlinker Adds Biotechnology Instrumentation - International Market Trends 4Reportlinker Adds Biotechnology Instrumentation - International Market Trends 5Reportlinker Adds Biotechnology Instrumentation - International Market Trends 6Reportlinker Adds Biotechnology Instrumentation - International Market Trends 7Reportlinker Adds Pharmacodynamic Assays 2Reportlinker Adds Pharmacodynamic Assays 3Reportlinker Adds Pharmacodynamic Assays 4SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 2SciVal Spotlight Gaining Momentum Across the Globe as More Universities Seek Multidisciplinary View of Research Performance 3
Other Biology Technology:Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Evolution in the nanoworld 2Evolution in the nanoworld 3Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 2Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 3Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 4Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 5Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 6Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 7Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 8Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 9Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 10Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 11Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 12Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 13Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues 14